Decode 100% of the Genome with AI
We transform noisy data from whole genome sequencing into actionable insights covering coding and non-coding DNA.
Cutting-edge technology and precision at scale for research, drug discovery, and clinical diagnostics.
A spin-off from:
All-in-one AI powered platform for variant detection, prioritization, interpretation and data sharing
100% Genome Coverage
Fast Large-Scale Cohort Analysis
87% Fewer False Positives
Complete Variant Detection
Full Multi-Omics Integration
What we offer
Comprehensive genome analysis
Our software analyses the whole genome on cohort, family or individual level tailored to your needs.
Variation detection and ranking
Through the detection, ranking, and prioritization of mutations, you are provided with a manageable list of suggested pathogenic mutations.
Cutting edge AI Technology
Detection
High-quality detection methods that decrease false-positive structural variants by 87%, including DEL, DUP, INS and INV.
Prioritization
Disease-agnostic AI tool ranks over 80% of known pathogenic variants in the top 10. On top of that, we created a disease-specific scoring system with over 90% accuracy, it ensures precise prioritization for more reliable research outcomes.
Discover our Platform
Get a personalized walkthrough of our platform and see how it can benefit your needs.
Resources
Lucid Genomics at Festival of Genomics & Biodata 2025
2025 Jan. 31
During the FoG 2025 in London, we were able to connect to many people and show our software and solutions.
Bayer Co.Lab opening in Berlin
2024 Nov. 10
Lucid Genomics and other inspiring start-ups were invited to pitch at the Bayer Co.Lab opening in Berlin.
Achim Geppert as Co-Founder and Chief Commercial Officer
2025, March 3
As of February 1st, Achim Geppert joined as third Co-Founder and Chief Commercial Officer.
Stay informed
Stay informed with the latest updates, news, and insights delivered to your inbox.